Tech Note

Multiplexing microbes on the PacBio^® Sequel^™: Feasibility, benefits, and recent developments

What you'll learn

To evaluate the multiplexing feasibility and assembly quality, GENEWIZ sequenced four E. coli genomes on one PacBio^® Sequel^™ SMRT cell. This study proves the feasibility of multiplexing and highlights the key advantages of the PacBio Sequel platform as compared to its predecessor, the RSII. Discover the riveting results in this GENEWIZ-exclusive Tech Note!

The key advantages of the PacBio Sequel platform as compared to the RSII

The cost and time involved to sequence 16 5Mb genomes by multiplexing on Sequel or non multiplexed sequencing on RSII

Feasibility, benefits and recent developments

Download Case Study

Share on Social Media:

For technical support questions, please contact our Next Generation Sequencing team

(877) 436-3949 ext. 1 | NGS@genewiz.com